Let's talk

What is XALKORI?

XALKORI is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. It is not known if XALKORI is safe and effective in children.

Non-small cell lung cancer & its treatment

NSCLC & its treatment

What we know about non-small cell lung cancer (NSCLC)

From the day you’re diagnosed with NSCLC, life changes. You begin a fight that can leave you exhausted, frustrated, and scared. But learning more about your NSCLC could give you the confidence to partner with your doctors and make informed decisions. And that may help you feel more in control.

NSCLC accounts for 85% to 90% of all lung cancer cases. It can be divided into 3 main types.

  • Adenocarcinoma

    Adenocarcinoma is the most common NSCLC, predominantly affecting people who smoke, or used to smoke, but it is also the most common type of lung cancer seen in nonsmokers. Comprising approximately 40% of all lung cancer cases, adenocarcinoma is more common in women, and it is more likely to affect younger people than other types of lung cancer. Adenocarcinoma is usually found in the outer region of the lung. It tends to grow more slowly.

  • Squamous cell carcinoma

    Squamous cell carcinoma occurs in the cells that line the airways inside your lungs. Squamous cell carcinoma usually begins in the early development of these cells, and accounts for approximately 25% to 30% of all lung cancer cases. It is often linked to a history of smoking and tends to be found in the middle of the lungs, near a large airway.

  • Large cell carcinoma

    Large cell carcinoma accounts for around 10% to 15% of lung cancers. It often grows and spreads fast, and may appear anywhere in the lung.

How NSCLC Begins

NSCLC has traditionally been associated with certain risk factors, such as smoking. But many people are surprised to learn that it can affect anyone. Men and women of different ages and races, people who smoke, used to smoke, or who never smoked can get it.

Doctors believe that long-term exposure to cancer-causing substances can damage the cells in your lungs. This damage may cause genetic alterations or defects in these cells, but changes can also occur when there is no apparent cause. Some of these defects can cause the cells to grow and multiply abnormally, and this can lead to cancer.

Treating NSCLC

For NSCLC today, the general treatment options may include: surgery, radiation therapy, chemotherapy, and biomarker-driven therapy. These are often used in various combinations, depending on what is best suited to the person’s cancer.

  • Surgery

    Surgery is more often an option at the early stages when the cancer is localized and has not spread outside the lung. It is often part of a plan that includes other types of treatments.

  • Radiation therapy

    Radiation therapy is a treatment option that kills cancer cells with X-rays or other radioactive particles. External beam radiation is delivered from outside the body and directed at the cancer. Internal radiation therapy (Brachytherapy) uses a radioactive pellet that is placed inside the lung, directly into the cancer or next to it.

  • Chemotherapy

    The aim of chemotherapy is to use anti-cancer drugs to kill cancer cells. These drugs may be injected or taken orally. They are usually given in 4 to 6 cycles, with each cycle lasting 3 to 4 weeks. Because these drugs get into the bloodstream and circulate throughout the body, this type of treatment is useful for cancers that have spread.

  • Biomarker-driven therapy

    Thanks to breakthroughs in genetics over the past decade, biomarker-driven therapy is giving doctors another important option for treating some people with NSCLC. For people whose tumors test positive for certain genetic factors, it may be possible to devise a course of treatment based on the particular genetic makeup of the tumor.

On the next page, we’ll discuss biomarker testing and what it means for NSCLC treatment today.

> NEXT, LET’S TALK: BIOMARKER TESTING & NSCLC TREATMENT

Non-small cell lung cancer (NSCLC):

A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The 3 main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Biomarker-driven therapy:

A type of treatment that is designed to block the action of cancer-causing genes or proteins.

 

Indications

XALKORI is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. It is not known if XALKORI is safe and effective in children.

Important Safety Information

XALKORI® (crizotinib) may cause serious side effects, some of which may include:

Liver problems — XALKORI may cause life-threatening liver injury that may lead to death. Your healthcare provider should do blood tests at least every month to check your liver during treatment with XALKORI. Tell your healthcare provider right away if you get any of the following new or worsening symptoms:

  • yellowing of your skin or the white part of your eyes
  • severe tiredness
  • dark or brown (tea color) urine
  • nausea or vomiting
  • decreased appetite
  • pain on the right side of your stomach
  • bleed or bruise more easily than normal
  • itching

Lung problems (pneumonitis) — XALKORI may cause life-threatening lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including:

  • trouble breathing or shortness of breath
  • cough with or without mucous
  • fever

Heart problems — XALKORI may cause very slow, very fast, or abnormal heartbeats. Your healthcare provider may check your heart during treatment with XALKORI. Tell your healthcare provider right away if you feel dizzy or faint or have abnormal heartbeats. Tell your healthcare provider if you take any heart or blood pressure medicines.

Vision problems — Vision problems are common with XALKORI. These problems usually happen within 1 week of starting treatment with XALKORI. Vision problems with XALKORI can be severe and may cause partial or complete loss of vision in one or both eyes. Your healthcare provider may stop XALKORI and refer you to an eye healthcare provider if you develop severe vision problems during treatment with XALKORI. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:

  • double vision
  • seeing flashes of light
  • blurry vision
  • light hurting your eyes
  • new or increased floaters

Before you take XALKORI, tell your healthcare provider if you:

  • have heart problems, including a condition called long QT syndrome
  • have liver or kidney problems
  • have vision or eye problems
  • have any other medical conditions
  • are pregnant, or plan to become pregnant. XALKORI can harm your unborn baby.
    • > Females who are able to become pregnant should use effective birth control during treatment with XALKORI and for at least 45 days after the final dose of XALKORI.
    • > Males who have female partners who can become pregnant should use condoms during treatment with XALKORI and for at least 90 days after the final dose of XALKORI.
    • > Talk to your healthcare provider about birth control methods that may be right for you.
    • > If you or your partner becomes pregnant, tell your healthcare provider right away.
  • are breastfeeding or plan to breastfeed. It is not known if XALKORI passes into your breast milk. Do not breastfeed during treatment with XALKORI and for 45 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

You should not drink grapefruit juice or eat grapefruit during treatment with XALKORI. It may increase the amount of XALKORI in your blood to a harmful level.

The most common side effects of XALKORI include:

  • vision problems
  • nausea
  • diarrhea
  • vomiting
  • swelling of your hands, feet, face, and eyes
  • constipation
  • increased liver function blood test results
  • tiredness
  • decreased appetite
  • upper respiratory infection
  • dizziness
  • feeling of numbness or tingling in the extremities

XALKORI can cause changes in your vision, dizziness, and tiredness. If you have these symptoms avoid driving a car, using machinery or doing anything that needs you to be alert.

XALKORI may cause decreased fertility. In females, this could affect your ability to become pregnant. In males, this could affect your ability to father a child.

These are not all of the possible side effects of XALKORI. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

 

Indications

XALKORI is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. It is not known if XALKORI is safe and effective in children.

If you are uninsured or don’t have sufficient coverage for XALKORI, call 1-877-744-5675 to talk to a counselor at Pfizer RxPathways®. They are available Monday through Friday, 8 AM to 8 PM ET and can help verify whether you are eligible for patient assistance.

The product information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.